Cholestin lovastatin content renders product unapproved new drug, FDA concludes.
This article was originally published in The Tan Sheet
Executive Summary
LOVASTATIN IN CHOLESTIN RELEVANT "ARTICLE" FOR DEFINING REGULATORY STATUS, FDA determines in a May 20 letter to Pharmanex outside counsel Stuart Pape (D.C. firm of Patton Boggs). The agency has concluded Cholestin is an unapproved new drug, not a dietary supplement, because it contains lovastatin, which was not "marketed as a dietary supplement or food" before the ingredient was involved in recognized clinical studies or approved for prescription drug use in 1987 as Merck's cholesterol-reducer, Mevacor.
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning